Related Experiment Video
Updated: Jun 22, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Thrombomodulin in the treatment of atherothrombotic diseases
Yi-Heng Li1, Guey-Yueh Shi, Hua-Lin Wu
1Department of Internal Medicine,Cheng Kung University, Tainan, Taiwan.
Abstract:
Thrombomodulin (TM) is a membrane-bound glycoprotein receptor r thrombin in the protein C activation pathway. Since its discovery in the 1980s as an anticoagulant protein, recent data suggest that TM plays an important role in modulating cellular proliferation, adhesion and inflammation. A soluble TM fragment has been produced with recombinant DNA technology that can bind thrombin and activate protein C. Soluble TM has received much attention because of its potential clinical applications. This article will examine recent advances in the understanding of TM's novel physiological function and review the molecular mechanisms of TM's anti-inflammatory effect. This review will also summarize TM data generated from animal studies and clinical trials to date and will focus on the role of TM in treating thrombotic, atherosclerotic and other inflammation-related diseases. These emerging data show that soluble TM is a promising agent that may provide potential therapies to modulate the pathophysiological process of atherothrombotic and other inflammatory diseases in the near future.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clot Retraction and Fibrinolysis
